What is the clinical evidence from this study?

Population: HIV-1 (preclinical model). Intervention: mRNA-galsomes vs. mRNA-LNPs or PBS. Primary outcome: Gag-specific T cell responses and cytotoxicity.

What does this research mean for the field?

Immunization with nucleoside-modified mRNA-galsomes and mRNA-LNPs elicits robust, cytotoxic Gag-specific CD8+ T cell responses across multiple lymphoid organs in mice. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

October 30, 2024Molecular Therapy — Nucleic AcidsOpen Access

The role of mRNA-galsomes and LNPs in enhancing HIV-specific T cell responses across various lymphoid organs

View Full Paper

Ask AI

Bookmark

Key result

mRNA-galsomes match mRNA-LNPs in eliciting robust Gag-specific CD8+ T cell responses in mice.

Why the study?

mRNA nanoparticles have been investigated for prophylactic HIV vaccination, but their effectiveness has not been widely studied in therapeutic vaccination.

Does immunization with mRNA-galsomes enhance HIV-specific T cell responses compared to standard mRNA-LNPs in mice?

Population

C57BL/6 mice

Comparison

mRNA-galsomes vs mRNA-LNPs

Design

Preclinical animal study

Authors

SDSigrid D’haeseVrije Universiteit Brussel SRSabine den RooverVrije Universiteit Brussel RVRein VerbekeGhent University Hospital

Discussion

Member takes

Implication

Comparable responses in mice are hypothesis-generating for mRNA HIV vaccines; human trials needed before any clinical consideration.

Structured PICO

Does immunization with mRNA-galsomes enhance HIV-specific T cell responses compared to standard mRNA-LNPs in mice?

Population

Female C57BL/6 and OT-I mice aged 6-12 weeks used in a preclinical model to evaluate therapeutic HIV-1 mRNA vaccines.

Intervention

Intramuscular immunization with nucleoside-modified mRNA encoding ovalbumin (li80tOVA) or HIV-1 Gag mRNA formulated in mRNA-galsomes (containing α-galactosylceramide as an adjuvant)

Comparator

mRNA lipid nanoparticles (mRNA-LNPs)

Outcome

Proliferation levels of specific CD8+ T cells in lymphoid tissues across various anatomical sitessurrogate

Both mRNA-galsomes and mRNA-LNPs effectively induce HIV-specific CD8+ T cell responses with cytolytic capacity in lymphoid tissues, highlighting their potential for therapeutic HIV vaccination.

Limitations

The study exclusively focused on myeloid DC subsets, and other APCs such as plasmacytoid DCs, macrophages, and monocytes were not taken into consideration.
Preclinical animal model (mice) which may not fully translate to human people living with HIV.
Did not evaluate oral or mucosal administration routes despite the focus on gut-associated lymphoid tissues.

Cite This Study

D’haese et al. (2024) studied HIV-1 (preclinical model). mRNA-galsomes vs. mRNA-LNPs or PBS was evaluated on Gag-specific T cell responses and cytotoxicity. Immunization with nucleoside-modified mRNA-galsomes and mRNA-LNPs elicited comparable, robust Gag-specific polyfunctional CD8+ T cell responses and cytotoxicity across various lymphoid organs in mice.

synapsesocial.com/papers/6aa94d9e6dc8754dbe62ed38 https://doi.org/10.1016/j.omtn.2024.102372

View Full Paper

Ask AI

Bookmark

The role of mRNA-galsomes and LNPs in enhancing HIV-specific T cell responses across various lymphoid organs

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

The role of mRNA-galsomes and LNPs in enhancing HIV-specific T cell responses across various lymphoid organs

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider